Literature DB >> 7577472

Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin.

C De Giovanni1, C Melani, P Nanni, L Landuzzi, G Nicoletti, F Frabetti, C Griffoni, M P Colombo, P L Lollini.   

Abstract

Three human rhabdomyosarcoma cell lines were used to investigate the presence of autocrine loops based on the production of insulin-like growth factor (IGF)-II, basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF)/transforming growth factor (TGF)-alpha and of their corresponding receptors, and whether these loops affect cell proliferation and myogenic differentiation. Two cell lines, RD/18 and CCA, deriving from tumours of the embryonal histotype, showed the presence of both growth factors and receptors which make possible three different autocrine loops, while the alveolar RMZ-RC2 cell line lacked that based on the EGF receptor. Culture of rhabdomyosarcoma cells in the presence of specific blocking antibodies, directed to a component of single autocrine loops, inhibited cell proliferation (up to 50%), without inducing myogenic differentiation. Suramin, a drug which non-selectively interferes with the binding of growth factors to their cellular receptors, was used to block all the autocrine loops simultaneously. In CCA and RMZ-RC2 cells suramin was able to induce a significant increase (up to 3-fold) in the proportion of myosin-positive cells over control cultures. Therefore rhabdomyosarcoma cells of embryonal and alveolar histotype can show a redundancy of growth-sustaining autocrine loops. Suramin could interfere with them by acting on both growth inhibition and induction of myogenic differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577472      PMCID: PMC2033961          DOI: 10.1038/bjc.1995.490

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Terminally differentiated postmitotic tumor cells in a rat rhabdomyosarcoma cell line.

Authors:  H E Gabbert; C D Gerharz; R Engers; W Müller-Klieser; R Moll
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1988

2.  Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA).

Authors:  C De Giovanni; P Nanni; G Nicoletti; C Ceccarelli; K Scotlandi; L Landuzzi; P L Lollini
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

3.  Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs.

Authors:  P L Lollini; C De Giovanni; B Del Re; L Landuzzi; G Nicoletti; G Prodi; K Scotlandi; P Nanni
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

4.  12-O-tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line.

Authors:  S Aguanno; M Bouchè; S Adamo; M Molinaro
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

5.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

Authors:  T Kawamoto; J D Sato; A Le; J Polikoff; G H Sato; J Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

6.  Involvement of growth factor receptors in the mammalian UVC response.

Authors:  C Sachsenmaier; A Radler-Pohl; R Zinck; A Nordheim; P Herrlich; H J Rahmsdorf
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

7.  The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line.

Authors:  A J Garvin; W S Stanley; D D Bennett; J L Sullivan; D A Sens
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

8.  Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors.

Authors:  L Schweigerer; G Neufeld; A Mergia; J A Abraham; J C Fiddes; D Gospodarowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

Review 9.  Effects of growth factors on myogenic differentiation.

Authors:  J R Florini; K A Magri
Journal:  Am J Physiol       Date:  1989-04

10.  RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin.

Authors:  P Nanni; S Schiaffino; C De Giovanni; G Nicoletti; G Prodi; B Del Re; V Eusebi; C Ceccarelli; L Saggin; P L Lollini
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

View more
  7 in total

1.  Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.

Authors:  Hua Wang; Guang-Hua Yang; Hong Bu; Qiao Zhou; Li-Xin Guo; Shou-Li Wang; Lv Ye
Journal:  Int J Exp Pathol       Date:  2003-06       Impact factor: 1.925

2.  The chaperone activity of GRP94 toward insulin-like growth factor II is necessary for the stress response to serum deprivation.

Authors:  Olga Ostrovsky; Noreen T Ahmed; Yair Argon
Journal:  Mol Biol Cell       Date:  2009-01-21       Impact factor: 4.138

3.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

4.  Targeting angiogenesis in childhood sarcomas.

Authors:  Hemant K Bid; Peter J Houghton
Journal:  Sarcoma       Date:  2010-12-09

5.  Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells.

Authors:  C De Giovanni; P Nanni; A Sacchi; S Soddu; I Manni; G D'Orazi; S Bulfone-Paus; T Pohl; L Landuzzi; G Nicoletti; F Frabetti; I Rossi; P L Lollini
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

6.  Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

Authors:  Carla De Giovanni; Patrizia Nanni; Lorena Landuzzi; Marianna L Ianzano; Giordano Nicoletti; Stefania Croci; Arianna Palladini; Pier-Luigi Lollini
Journal:  BMC Cancer       Date:  2019-02-07       Impact factor: 4.430

7.  The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.

Authors:  W Zumkeller
Journal:  Sarcoma       Date:  1998
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.